Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. for allegedly misleading investors regarding the launch and demand for its Inspire V device, leading to significant stock price declines and loss of market capitalization [1][2][3]. Group 1: Allegations and Misrepresentation - The Complaint claims that Defendants made false statements and failed to disclose critical information about the market demand for Inspire V and the necessary steps for its successful launch [2]. - It is alleged that Defendants misled investors into believing that demand for Inspire V was strong, while in reality, the launch faced significant delays due to incomplete training and onboarding at treatment centers [2]. - The Complaint states that the rollout of Inspire V was hindered by poor demand and excess inventory, resulting in a drastic reduction of the Company's 2025 earnings guidance by over 80% [2]. Group 2: Stock Price Impact - Following the revelation of these issues on August 4, 2025, Inspire Medical's stock price plummeted by more than 32%, from $129.95 to $87.91 per share, erasing $1.2 billion in market capitalization in one day [3]. - The stock price had previously reached a high of $216.71 per share on September 23, 2024, indicating a nearly 60% decline, equating to a loss of billions in market capitalization [3]. Group 3: Class Action Participation - Investors who purchased Inspire Medical common stock during the Class Period may seek to be appointed as lead plaintiffs in the class action lawsuit, as per the provisions of the Private Securities Litigation Reform Act of 1995 [4]. - Interested investors are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on January 5, 2026 [5].

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, inclusive (the “Class Period”), have until January 5, 2026 to seek appointment as lead plaintiff of the Inspire Medical class action lawsuit. Captioned City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems, Inc., No. 25-cv-04247 (D. Minn.), the Inspire ...

Nov 6, 2025 6:48 PM Eastern Standard Time Grant & Eisenhofer Files Class Action Lawsuit Against Inspire Medical Systems, Inc. Share NEW YORK--(BUSINESS WIRE)--Today, Grant & Eisenhofer P.A. filed a class action lawsuit on behalf of City of Pontiac Reestablished General Employees' Retirement System against Inspire Medical Systems, Inc. ("Inspire Medical†or the "Company†) and three of the Company's senior executives, including CEO Timothy Herbert, CFO Richard Buchholz, and Chief Strategy and Growth Officer ...

Key Takeaways Inspire Medical reported Q3 EPS of 38 cents, ahead of the expected loss of 15 cents.INSP's Q3 revenues rise to $224.5 million, driven by market reach and therapy awareness.Inspire Medical raised 2025 EPS guidance to 90 cents to $1.00 while maintaining revenue outlook.Inspire Medical Systems, Inc. (INSP) delivered adjusted earnings per share (EPS) of 38 cents in third-quarter 2025, down 36.7% year over year. The figure compares with the Zacks Consensus Estimate of a loss of 15 cents.INSP’s Reve ...

Core Insights - Inspire Medical Systems Inc reported better-than-expected third-quarter financial results, with earnings of 38 cents per share, surpassing the analyst consensus estimate of a loss of 19 cents per share [1] - The company also reported quarterly sales of $224.501 million, exceeding the analyst consensus estimate of $220.467 million [1] Financial Guidance - Inspire Medical Systems raised its FY2025 GAAP EPS guidance from a range of $0.40-$0.50 to $0.90-$1.00, while affirming sales guidance of $900 million-$910 million [2] Management Commentary - Tim Herbert, Chairman and CEO, highlighted the productive third quarter focused on the transition to the Inspire V system and presented clinical evidence of enhanced performance at recent industry meetings [3] Stock Performance - Following the earnings announcement, Inspire Medical shares increased by 17%, trading at $86.46 [3] Analyst Reactions - Wells Fargo upgraded Inspire Medical Systems from Equal-Weight to Overweight, lowering the price target from $101 to $90 [6] - JP Morgan maintained a Neutral rating, cutting the price target from $110 to $82 [6] - Truist Securities reiterated a Hold rating, reducing the price target from $90 to $84 [6] - RBC Capital maintained an Outperform rating, lowering the price target from $150 to $125 [6] - Piper Sandler reiterated an Overweight rating, reducing the price target from $150 to $135 [6]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - The company reported strong third-quarter results with a revenue of $224.5 million, a 10% increase year-over-year, and reaffirmed its full-year revenue guidance of $900 to $910 million, representing a growth of 12% to 13% compared to 2024 [8][15][18] - The Inspire 5 system has shown significant clinical performance improvements, including an 87% inspiratory overlap with patient breathing and a 20% reduction in surgical times [4][5] - The company is experiencing positive feedback from clinical studies, indicating that Inspire therapy can reduce long-term cardiovascular morbidity and mortality compared to CPAP treatment [6][7] Financial Performance - Total revenue for the third quarter was $224.5 million, with U.S. revenue at $214.4 million, a 9% increase from the previous year [15] - Operating income for the quarter was $9.6 million, down from $14.3 million in the prior year, with net income at $9.9 million compared to $18.5 million [16][17] - The company increased its earnings per share guidance to 90¢ to $1, up from a previous range of 40 to 50¢ [8][19] Market and Product Development - The Inspire 5 launch is progressing well, with over 98% of physician training completed and over 75% of centers onboarding SleepSync [7][8] - The company is focusing on expanding its market access and has seen a positive trend in reimbursement, with CMS finalizing an 11% increase for CPT code 64568 [9][10] - The company is also leveraging the growing interest in sleep health driven by GLP-1 treatments, which is bringing more patients into clinics [11][12] Strategic Initiatives - The company is committed to enhancing patient outcomes through innovation and clinical evidence, with ongoing investments in medical education and patient marketing [7][13] - A new advertising campaign has been launched to promote Inspire therapy, featuring notable partnerships to increase awareness [9] - The company is actively working to transition centers from Inspire 4 to Inspire 5, with a focus on training and support for lower-volume centers [40][41] Future Outlook - The company anticipates a revenue growth of 10% to 11% for 2026, influenced by the ongoing adoption of Inspire 5 and the impact of GLP-1 treatments [22][23] - The company is monitoring competitive dynamics and expects to provide formal guidance for 2026 in January [22][58] - The company is also addressing operational efficiencies through territory management and optimizing the ratio of territory managers to field clinical representatives [77][78]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $224.5 million, a 10% increase from $203.2 million in Q3 2024 [15] - U.S. revenue was $214.4 million, up 9% from $195.8 million in the prior year [15] - Gross margin improved to 85.8% from 84.1% year-over-year, driven by increased sales volume and a favorable sales mix of Inspire 5 [15] - Operating income decreased to $9.6 million from $14.3 million in the prior year [16] - Net income for the quarter was $9.9 million, down from $18.5 million year-over-year [16] - Adjusted EBITDA was $44 million, slightly down from $44.5 million in the prior year [17] - The company increased its earnings per share guidance to $0.90-$1, up from $0.40-$0.50 previously [9] Business Line Data and Key Metrics Changes - Inspire 5's U.S. launch showed significant progress, with physician training over 98% complete and contracting over 90% complete for centers [8] - The Inspire 5 system demonstrated an 87% inspiratory overlap with patients' breathing, indicating strong clinical performance [5] - The company reported a 20% reduction in surgical times based on clinical studies [4] Market Data and Key Metrics Changes - Revenue outside the U.S. was $10.1 million, a 37% increase year-over-year [15] - The Centers for Medicare & Medicaid Services (CMS) finalized an 11% increase in the physician fee schedule for CPT code 64568, effective January 1, 2026 [10] Company Strategy and Development Direction - The company remains focused on patient outcomes and innovation, investing in clinical evidence and medical education [4] - Strategies include training advanced practice providers and increasing the capacity of provider partners to treat more patients [13] - The company is optimistic about the future, with plans to drive long-term stakeholder value [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of growth heading into 2026, with an early indication of 10%-11% growth for next year [22] - The company is mindful of near-term factors such as inventory transitions and competitive activity but remains focused on executing its growth strategy [23] - Management highlighted the positive impact of GLP-1s on patient flow into clinics, which could benefit Inspire therapy [12] Other Important Information - The company completed $50 million in share repurchases during the quarter, totaling $125 million year-to-date [17] - The company ended the quarter with $411 million in cash and investments, allowing for continued investment in growth strategies [17] Q&A Session Summary Question: Thoughts on 2026 planning and cadence - Management is focused on finishing Q4 strong and is still early in the 2026 planning process, indicating potential accelerated growth from Q3 [22] Question: Trends in business for October and Q4 guidance - Management noted strong trends with Inspire 5 and expects to see consistent execution and operational benefits from tighter integration across departments [28] Question: Transitioning centers to Inspire 5 - Management confirmed that while many centers are transitioning to Inspire 5, some will continue to use Inspire 4 for economic reasons [32] Question: Operating expenses and sustainability - Management indicated that while there is a focus on expense control, investments in R&D and marketing will continue, with a disciplined approach to spending [36] Question: Impact of new competitors on market growth - Management stated that it is early days for new competitors and they will continue to monitor the situation closely [64] Question: Economic considerations for centers using Inspire 4 - Management clarified that economic factors are more related to site of service reimbursement rather than physician reimbursement rates [82] Question: Operating expenses trend for 2026 - Management expects a slight increase in DTC spending but does not anticipate it to grow at the same rate as revenue [83]